Toward staging differentiation for posttraumatic stress disorder treatment

Area of Science:

• Psychiatry
• Neuroscience
• Clinical Psychology

Background:

• Current posttraumatic stress disorder (PTSD) guidelines lack stage-specific treatment recommendations.
• Evidence suggests distinct PTSD symptom trajectories and phenotypes relevant for staging.
• Staging models are successfully used in managing other medical and psychiatric disorders.

Purpose of the Study:

• To propose a novel, neurobiologically informed, four-stage model for classifying posttraumatic stress disorder (PTSD).
• To address the need for stage-based treatment decision-making in PTSD.
• To enhance personalized treatment strategies and clinical trial frameworks.

Main Methods:

• A state-of-the-art review synthesizing existing research on staging models.
• Application of staging concepts from other disorders to PTSD.
• Development of a four-stage model based on chronicity and symptom progression.

Main Results:

• A proposed four-stage PTSD model (Stage 0 to Stage 4), detailing progression from asymptomatic to severe, chronic illness.
• Integration of neurobiological markers, information processing, stress reactivity, and consciousness dimensions into the staging typology.
• Advocacy for recognizing treatment resistance as a distinct phenomenology to inform interventions.

Conclusions:

• A staging perspective for PTSD is crucial for tailoring interventions to patient needs and progression risk.
• The proposed model can optimize the organization of biomarker data and guide healthcare service delivery.
• A trajectory-based, neurobiologically driven PTSD typology facilitates personalized treatment planning and evaluation.